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Background and Objective. Acute generalized, wide-
spread bleeding is often related to disseminated
intravascular coagulation (DIC), a pathologic process
which complicates the clinical course of many dis-
eases and is characterized by huge amounts of throm-
bin and plasmin within the circulation. The final result
is the consumption of platelets, coagulation factors
and inhibitors, as well as secondary hyperfibrinoly-
sis, all leading to diffuse hemorrhage and micro-
thromboses. This review article examines the pre-
sent attitudes to the diagnosis and treatment of overt
DIC in clinical practice, emphasizing the importance
of an accurate differential diagnosis from some oth-
er processes characterized by acute generalized,
widespread bleeding. 
Information Sources. The authors have been working
in this field, both at experimental and clinical levels,
contributing original papers for many years. In addi-
tion, material examined in this review includes arti-
cles published in journals covered by MedLine®,
recent reviews in journals with high impact factor
and in relevant books on hemostasis and thrombosis. 
State of Art and Perspectives. DIC is an intermediary
mechanism of disease which complicates the clinical
course of many well-known disorders. Although the
systemic hemorrhagic syndrome is the predominant
clinical manifestation, massive intravascular throm-
bosis frequently occurs contributing to ischemia and
associated organ damage, making the mortality rate
of this condition high. Current concepts on the patho-
physiology, laboratory diagnosis and management of
DIC are presented. Complex pathophysiological inter-
relations make the diagnosis of the etiology of the DIC
difficult in clinical practice, although simple tests are
useful for identification of patients with the process.
Laboratory diagnosis of DIC is mainly based on screen-
ing assays, which allow a rapid diagnosis, whereas
some other highly sensitive but more complex assays
are not always available to routine clinical laborato-
ries. The management of DIC is based on the treat-
ment of the underlying disease, supportive and
replacement therapies and the control of the coagu-
lation mechanisms. Although some advances have
been achieved, management decisions are still con-
troversial, so that therapy should be highly individual-
ized depending on the nature of the DIC and severity
of clinical symptoms. Many syndromes sharing com-
mon findings with DIC, such as primary hyperfibrinoly-
sis or thrombotic thrombocytopenic purpura, should
be excluded. Finally, new therapeutic approaches to
the management of this potentially catastrophic syn-
drome are required.
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The acute appearance of a general and wide-spread hemorrhagic syndrome, associatedwith a great number of underlying diseases, is
a characteristic finding of disseminated intravascu-
lar coagulation (DIC). In clinical practice, some dis-
orders closely related to DIC, such as primary hyper-
fibrinolysis, thrombotic thrombocytopenic purpura
(TTP) and the complex hemostatic abnormalities
associated with severe hepatic disorders can mimic
a similar clinical condition, often making differen-
tial diagnosis difficult. This review will be restricted
to bleeding syndromes secondary to DIC. The
remaining processes will be considered only in order
to mention them as differential diagnoses and list
their treatments.
As McKay previously described,1 DIC is an inter-
mediary mechanism of disease associated with a variety
of disorders and clinical conditions. It probably rep-
resents a hyperactive response of the physiologic
control mechanisms to a wide number of tissue
insults. Although sometimes DIC can become itself
the primary mechanism of disease, in most cases it
is an epiphenomenon that complicates a previously
established clinical entity.
DIC can appear in the evolution of many diseases
(Table 1).2-6 In hospital clinical practice, the most
frequent of these are infections, representing 25-30%
of the cases reported in the largest series,7-9 followed
by neoplastic processes, obstetrical accidents, crush
injuries and major surgical operations, and liver dis-
eases.
All these conditions can activate the coagulation
system by triggering the generation of thrombin with-
in the systemic circulation. This activation occurs as
a direct effect of a broad spectrum of endothelial or
tissue lesions. Normal endothelium plays a key role
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in hemostatic regulation through a variety of mech-
anisms, such as secretion or cell surface expression of
heparan sulfate proteoglycan, thrombomodulin,
prostacyclin, von Willebrand factor (vWF), tissue fac-
tor (TF), tissue plasminogen activator (t-PA) and
plasminogen activator inhibitor 1 (PAI-1).10 Endothe-
lial damage may lead to disturbance or loss of its reg-
ulatory functions as a result of physical injury, infec-
tious pathogens or toxins or inflammatory mediators
such as bacterial endotoxins, activated complement,
interleukin 1 (IL-1), tumor necrosis factor-a (TNF-a)
or neutrophil proteases exposure.11-13 As far as con-
cerns tissue lesions, these lead to some procoagulant
material entering the circulation, particular TF, whose
contribution to the activation of coagulation has
been demonstrated in experimental DIC studies.14,15
The contribution of the contact system, particularly
factor XII, to the activation of coagulation in DIC is,
however, uncertain, although a role for the develop-
ment of hemodynamic disorders associated with DIC
and possibly for the activation of the fibrinolytic sys-
tem has been proposed.16-19
The activation of coagulation after a triggering
event can be promoted directly or by the mediation of
cytokines, mainly TNF-a and IL-1,12,13,20-25 contribut-
ing to the development of the theoretically well-dif-
ferentiated stages of the pathophysiological mecha-
nism of DIC (Figure 1). However, in clinical practice
these stages are usually intertwined. Generation of
circulating thrombin is a direct consequence of the
activation of coagulation and responsible for fibrin
generation and platelet activation leading to small
vessel thrombosis thus producing ischemic lesions,
necrosis and functional failure of several organs. The
most commonly involved organs are the kidney, lung,
central nervous system and skin. Microangiopathic
hemolytic anemia also occurs as a result of fibrin
deposits within the microcirculation. Moreover, acti-
vation of coagulation causes consumption of platelets
and coagulation factors which contribute to hemor-
rhagic diatheses. Formation of intravascular fibrin
triggers fibrinolysis and the resulting generation of
plasmin through the action of t-PA released in
response to cytokines generated by the initial stimu-
lus. Activation of fibrinolysis represents a compen-
sating system that degrades microvascular fibrin clots.
The importance of such a mechanism is clearly shown
in patients with sepsis due to Gram-negative bacteria,
in whom endotoxin causes an increase in the levels of
PAI-126,27 as shown experimentally by the inhibitor lev-
els being higher in patients with DIC. This is an indi-
cator of a poor prognosis.28,29 The hyperplasminemia
becomes the main cause of the hemorrhagic diathe-
sis for two reasons: it induces the generation of great
quantities of fibrinogen degradation products (FDP)
and fibrin degradation products with a powerful anti-
hemostatic action, and reduces the plasma concen-
trations of coagulation factors because of its capaci-
ty to degrade them. Finally, natural coagulation
inhibitors, including antithrombin III (ATIII), proteins
C and S and the inhibitor of the extrinsic pathway
(TFPI) are also consumed, thus contributing to the
increased generation of thrombin and fibrin. The
pathophysiologic importance of these inhibitors has
been recently evaluated by several clinical and exper-
imental studies, although the results have not always
been concordant.14,20,30-40
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Table 1. Some causes of DIC.
1. Infections:
Gram-negative bacteria (endotoxin)
Gram-positive bacteria (mucopolysaccharides)
Viruses, fungi, protozoa, others
2. Neoplasia:
Solid tumors (adenocarcinomas, others)
Leukemia (promyelocytic, others)
3. Obstetric complications:
Amniotic fluid embolism
Abruptio placentae
Retained dead fetus
Septic abortion
Eclampsia
4. Trauma and tissue injury:
Brain injury
Crush injury
Burns
Surgery
Hyperthermia
Hypothermia
5. Liver disease:
Fulminant hepatic failure
Cirrhosis
Acute fatty liver of pregnancy
LeVeen shunt
Reye´s syndrome
6. Transfusion reactions:
Acute hemolytic transfusion reaction
Massive transfusion
7. Vascular disease:
Aortic aneurysm
Giant hemangioma (Kasabach-Merrit syndrome)
Malignant hypertension
Microangiopathic disorders
8. Venoms (vipers, other snakes, insects)
9. Respiratory distress syndromes
10. Shock
11. Drugs/Therapeutic agents:
Clotting factor concentrates (factor IX)
OKT3 monoclonal antibody
Interleukin-2
12. Miscellaneous:
Amyloidosis
Pancreatitis
Autoimmune diseases
Renal vascular disorders
Kawasaki disease
Anaphylaxis
Sarcoidosis
The intervention of normal compensatory process-
es must also be considered in the pathophysiology of
DIC. These processes include activation of the fibri-
nolytic system and the liver’s capacity to synthesize
coagulation factors, as well as production of platelets
in the bone marrow in order to compensate for con-
sumption, the clearance mechanisms of the factors
responsible for the initial stimulus, activated coagu-
lation factors and FDP by the mononuclear phago-
cytic system.
Therefore, the pathophysiology of DIC seems to be
controlled by two main mechanisms: generation of
thrombin and generation of plasmin. When the lat-
ter prevails, the clinical picture is characterized main-
ly by hemorrhagic symptoms. When generation of
thrombin dominates, the most important symptoms
are those caused by microvascular thrombosis and
organ ischemia. It is also important to consider the
acute or chronic nature of the process and the qual-
ity of activation, systemic or localized. This brief
review of the etiology and pathophysiology of DIC is
necessary in order to have a clear understanding of
the diagnosis and treatment approaches to the con-
dition.
The enormous complexity of the etiology, patho-
genesis and pathophysiology of DIC explains why it
generates controversy. In fact, it has been impossible
to define unified criteria and come to an agreement
on the most appropriate laboratory methods for
diagnosis. As regards the response to treatment and
survival, it should be noted that in many cases these
are more related to the primary cause of DIC than to
the treatment itself. Furthermore, there are no ran-
domized, prospective assays evaluating any of the
possible treatments. In this review we are trying to
update the actual knowledge about DIC searching
for maximum objectivity and avoiding any possible
dogmatism.
Clinical presentation of DIC
The diagnosis of DIC is essentially based on clini-
cal findings, the laboratory tests being useful for con-
firmation. Because of the great variety of primary
conditions which can cause DIC, the clinical presen-
tation may be very complex due to signs and symp-
toms directly related to the underlying disorder as
well as to those more characteristic of DIC. On the
other hand, DIC can be asymptomatic or manifest as
a severe picture of hemorrhage and/or thrombosis,
depending on the rates of fibrin formation and lysis.
Hemorrhages are the most frequent and common
presentation of the disease.9 In some cases bleeding
appears exclusively at the sites of venous or arterial
punctures or at surgical or traumatic wounds. More
common is the appearance of widespread petechiae,
purpura and hematomas, mucocutaneous bleeding,
hematuria, hemoptysis, gastrointestinal bleeding and,
occasionally, intracranial hemorrhage.41-43
The thrombotic manifestations may not be as clin-
ically obvious as hemorrhages in patients with DIC.
However, fibrin microthrombi often result in organ
dysfunction. All organs are potentially vulnerable.
Acute renal failure occurs frequently and acute tubu-
lar necrosis often accompanies this syndrome.42
Microvascular cerebral thrombosis causes cortical
dysfunction manifested by an altered state of con-
sciousness and coma.41 The combination of pul-
monary hemorrhages and thrombosis produces a
clinical picture resembling acute respiratory distress
syndrome.44 Thrombosis in large vessels is less fre-
quent except in the cases of an indwelling intravas-
cular catheter and the thrombosis associated with
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Figure 1. Pathophysiology of DIC.
chronic DIC secondary to malignancies when the
incidence of venous thromboembolism is high
(Trousseau syndrome).45
In some circumstances DIC is associated with pur-
pura fulminans characterized by skin hemorrhagic
necrosis and gangrene in the extremities of digits as a
consequence of arterial fibrin microthrombi. This syn-
drome appears in patients with Gram-negative bacte-
rial sepsis46,47 and also in other diseases48,49 and is
associated with reduced levels of proteins C and S.50
Two clinical situations related to purpura fulminans
are adrenal hemorrhagic necrosis (Waterhouse-Frid-
erichsen syndrome)51 and adrenal cortex necrosis.52
Laboratory diagnosis of DIC
Because of the complex pathophysiology of DIC
and its association with a variety of processes, the
laboratory manifestations in a given patient are
extremely variable and depend not only on findings
due to DIC but also on those due to the underlying
disease. In addition, the intensity and duration of
activation of blood coagulation and the consequent
thrombin formation, the state of natural clotting
inhibitors, the fibrinolytic system activation, the lev-
el of the liver function, the capacity of bone marrow
to produce platelets, the activity of the macrophage
system, the rate of blood flow and many other vari-
ables markedly influence the clinical picture and lab-
oratory findings.
As a consequence of all the above, it is not sur-
prising that the criteria for the diagnosis of DIC are
not well defined. It seems clear that the frequency of
diagnosis depends on two factors: the knowledge of
the occurrence of DIC in certain clinical settings and
the laboratory criteria used to make the diagnosis.
These criteria are extremely arbitrary and the analysis
should always take into account both the patient’s
underlying disease and the functional state of sever-
al organs.
Tests which are useful in assessing patients with
possible DIC can be divided into two categories
(Table 2): screening tests, which allow a rapid diag-
nosis, and thus being those really useful in the acute
forms, and more complex laboratory tests, highly sen-
sitive but time-consuming and not always available in
routine clinical laboratories, which are not, therefore,
of immediate clinical relevance, at least in the acute
forms. In fact, these latter tests should be restricted
to specialized laboratories and to clinical situations
allowing closer laboratory monitoring.
Screening Tests
If DIC is present, the global coagulation tests which
measure the capacity of thrombin generation, such as
the prothrombin time and the activated partial
thromboplastin time (APTT), should show pro-
longed coagulation times because of the decrease of
fibrinogen and factors II, V, VII, IX and X as a conse-
quence of consumption and plasmin-induced prote-
olysis of these factors as well as the presence of FDP
which inhibit fibrin polymerization. However, both
tests may be demonstrate normal or fast rate coag-
ulation in a percentage of patients with DIC,5,6,8,9,53
due to the presence of circulating activated clotting
factors or early fibrin degradation products rapidly
clottable by thrombin.6 This is the reason why both
tests are of little use in evaluating DIC. The thrombin
time may also be prolonged due to hypofibrinogen-
emia and interference of circulating FDP.54 However,
it may be sometimes normal or shortened and is in
any case difficult to standardize, so that this, too, is
also of little use in the diagnosis of DIC.
Thrombocytopenia is a constant feature in patients
with DIC and is related to shortened platelet sur-
vival.7,9,53 DIC also causes a qualitative defect in
platelets.55 The thrombocytopenia may also be relat-
ed to the underlying disorder, such as in acute pro-
myelocytic leukemia (APL) and sepsis.56,57 These fac-
tors explain why a fall in platelet count is neither sen-
sitive nor specific for DIC.
Fibrinogen concentration is reduced in approxi-
mately 50% of patients,7,9 but since it increases in sit-
uations such as after operations, in infection and dur-
ing pregnancy, the measured fibrinogen levels may
be normal in the presence of DIC.
FDP are elevated in 85 to 100% of patients with
DIC,3,5,7,9 although their levels are not always related
to the clinical course of DIC since they are influenced
by the degree of procoagulant activity, the fibrinolyt-
ic response and other factors such as the activity of
the macrophage system and renal clearance. The D-
dimer, which is specific for fibrin degradation prod-
ucts, is more specific but less sensitive than the latex
agglutination assays for FDP which measure the plas-
min degradation of fibrinogen and fibrin.58,59 Two
additional advantages of the D-dimer test over FDP
assays are the possibility of it being performed on
both plasma and serum and its lower susceptibility to
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Table 2. Laboratory diagnostic criteria of DIC.
1. Screening tests:
Thrombocytopenia
Hypofibrinogenemia
Elevated FDP and D-dimer
Decreased ATIII
Prolonged clotting times
Presence of schistocytes in peripheral blood smear
Positive tests for circulating soluble fibrin monomers
2. Other tests:
Decreased level of various clotting factors
Decreased protein C
Elevated F1+2, TAT and FPA
Decreased plasminogen and a2-antiplasmin
Elevated PAP, Bb 1-42 and Bb 15-42 peptides
Elevated PF4 and b-TG
artifacts caused by incomplete clotting of plasma
samples.58 Of the common tests used in assessing DIC
in patients, the D-dimer assay appears to be the most
abnormal in a high proportion of patients.6,60-62 It is
worthwhile noting that the increase of D-dimer is not
specific to DIC, since it can also occur in deep venous
thrombosis and pulmonary embolism, post-opera-
tively and in many other clinical conditions.63-66
Protamine sulfate or ethanol gel tests for circulating
soluble fibrin monomers were commonly used in the
diagnosis of DIC some years ago. However, although
specific they are not sensitive and are poorly stan-
dardized.8,9,67 More recently, new sensitive assays to
detect fibrin monomers have been incorporated which
can be useful in supporting a diagnosis of DIC,
although complex for routine use.68-71
Measurement of ATIII activity is considered anoth-
er screening test in patients with DIC since its value
markedly declines over time due to consumption.9,72,73
There is one exception, the DIC associated with APL,
where the functional level of ATIII remains normal,6
supporting the hypothesis that the coagulopathy in
APL is not caused by DIC but by primary fibrinolysis.74
Examination of the peripheral blood smear often
reveals schistocytes, but this finding is non-specific,
and the absence of schistocytes does not exclude
DIC.9,75,76 Differential diagnosis from TTP should be
made in the presence of a marked schistocytosis.
At present, no single laboratory test can be used to
confirm or exclude the diagnosis of DIC, but the com-
bination of a low platelet count, a decrease of
fibrinogen and ATIII and an increase of FDP – and
especially D-dimer – viewed in the context of the
patient’s underlying disease, appears to be the most
useful indicator. Less useful are the presence of schis-
tocytes in the blood smear, the prolongation of pro-
thrombin, APTT and thrombin times and the positiv-
ity of protamine sulfate or ethanol tests.
Other tests for the diagnosis of DIC
Coagulation factor assays, previously considered
to be useful, provide little information useful to the
diagnosis of DIC. The interpretation of results is dif-
ficult partly because many underlying diseases result
in increases and decreases in coagulation factors, and
partly because of the presence of activated clotting
factors in DIC which interfere with routine coagula-
tion assays.3,6 In particular, activities of factors II, V,
VII and X are likely to be low, whereas levels of factor
VIII are often normal in DIC, probably because the
factor VIII/von Willebrand released by endothelial
cells forms a complex which stabilizes factor VIII.77 A
decrease in circulating levels of protein C has also
been found in patients with DIC.31,34
The conversion of prothrombin to thrombin results
in the release of an inactive prothrombin fragment
1.2 (F1+2). Once thrombin is produced it can either
combine with ATIII to form a stable thrombin-
antithrombin (TAT) complex or induce fibrinogen
proteolysis with the liberation of fibrinopeptides A
and B (FPA and FPB). ELISA assays are now com-
mercially available to quantify the plasma levels of
F1+2, TAT and FPA in order to provide evidence of
activation of coagulation. Although there are numer-
ous reports showing a significant increase in these
molecular markers in patients with DIC,13,71,78-83 none
of these tests are widely used routinely for diagnosis.
Fibrinolytic system assays may provide useful infor-
mation in DIC. The global tests, such as the euglob-
ulin lysis time and fibrin plate assays provide little
information. However, in many cases there is a
decrease in plasminogen and a2-antiplasmin, due to
consumption, as well as a significant increase in plas-
min-antiplasmin (PAP) complexes, providing direct
evidence of in vivo plasmin generation, and in pep-
tides Bb 15-42 and Bb 1-42 derived from the prote-
olytic action of plasmin on fibrin and fibrinogen
respectively.5,6,84-89 A significant increase of PAI-1,
which was related to a poor prognosis in some cas-
es of DIC associated with sepsis or trauma, has also
been reported.28,29,90
Finally, increased platelet turnover and decreased
platelet survival is common in patients with DIC;
platelet factor 4 and b-thromboglobulin levels are
markers of platelet reactivity and release and are usu-
ally elevated in patients with DIC.91
At present, none of the mentioned tests are rou-
tinely used in patients with a suspicion of DIC and
there are not enough data regarding their clinical reli-
ability compared to the screening tests which are
cheaper, easier to perfom and more readily available
in clinical laboratories.
Differential diagnosis
Whereas there are few causes of acute, early onset,
massive and generalized hemorrhage in a patient with-
out a previous bleeding history and the cause is fre-
quently known in acquired coagulopathies, there are
some processes in which either the laboratory or clin-
ical manifestations resemble those occurring in DIC.
Septic patients may develop vitamin K deficiency or
thrombocytopenia in the absence of DIC,56,57,92,93 but
the differential diagnosis is relatively simple since these
conditions do not cause generation of FDP or D-
dimer, depletion of fibrinogen or consumption of ATI-
II. Significant bleeding due to reduced platelets and
coagulation factors and inhibitors rather than DIC
may be observed after massive transfusion or car-
diopulmonary bypass surgery as a result of hemodilu-
tion;94-96 the absence of D-dimer and FDP generation
may be useful in the differential diagnosis.
The coagulopathy associated with hepatic failure
may be very difficult to distinguish from DIC. The for-
mer’s characteristics include thrombocytopenia due
to platelet sequestration in the spleen, reduction of
fibrinogen and other coagulation factors and
inhibitors by abnormal synthesis, and elevated levels
of FDP and D-dimer due to delayed hepatic clearance
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and hyperfibrinolysis.97-100 In the cases in which diag-
nosis is difficult,101 the only way to differentiate DIC
in the presence of liver disease is to perform serial
measurements which, in the event of acute DIC, usu-
ally reveal a rapidly changing coagulopathy.58
TTP may be confused with DIC since it produces
acute illness with multiorgan dysfunction and dis-
seminated thrombotic and hemorrhagic phenome-
na. Ischemic symptoms are related to intraluminal
platelet thrombi and the hemorrhagic manifestations
depend on the degree of secondary thrombocytope-
nia due to platelet consumption. However, as shown
in Table 3, TTP does not usually cause consumption
of clotting factors or hyperfibrinolysis,102-104 making
the differential diagnosis from DIC easy. TTP patients
show an increase in thrombin generation and
reduced fibrinolysis probably related to an increase in
PAI-1.105 Although the etiology of TTP is not fully
understood, two hypotheses have been proposed to
explain the pathophysiology of this disease. For some
authors, the platelet aggregation is due to the lack of
a normally occurring platelet inhibitor106 or to a
platelet agglutinating protein,107 whereas for others
an abnormally large plasma von Willebrand factor
molecule would cause excessive platelet agglutina-
tion,108,109 although this multimeric pattern is not
always present.110 The prognosis of TTP has changed
dramatically in the last years with the combination of
plasmapheresis and plasma infusions to provide the
absent factor and to remove platelet-aggregating
substances.111-113
Finally, the possibility of unusual primary hyper-
fibrinolysis should also be taken into account in the
differential diagnosis of an acute, massive hemor-
rhagic disorder. The distinction from DIC may be very
difficult because the same underlying disease can
cause both processes, the bleeding symptoms may
be similar, high concentrations of D-dimer and FDP
can be present in both conditions, and lastly because
DIC and hyperfibrinolysis may coexist in patients. The
distinction is that in DIC the lysis is a physiologic
response to fibrin deposition in the microcirculation,
whereas in primary hyperfibrinolysis lysis occurs in
the macrocirculation, perhaps as a result of activa-
tors released by endothelial cells, or as a consequence
of the exogenous administration of plasminogen acti-
vators after thrombolytic therapy. That having been
said, the distinction between DIC and systemic hyper-
fibrinolysis may be extremely difficult (Table 3), even
when well-equipped laboratory facilities are available.
The simplest laboratory evaluation for the diagnosis
of hyperfibrinolysis is a shortened euglobulin lysis
time in the absence of thrombocytopenia and schis-
tocytosis.42 A correct differential diagnosis is very
important since the treatment of choice in hyperfib-
rinolysis is administration of fibrinolysis inhibitors,
such as e-aminocaproic acid (EACA) or tranexamic
acid, which can be dangerous in the presence of
DIC.114 Primary hyperfibrinolysis may appear in the
course of trauma, cardiopulmonary bypass surgery,
liver transplantation, liver cirrhosis, prostatic carci-
noma or congenital deficiencies of a2-antiplasmin
and PAI-1.2,5,42,100,115-117 On the other hand, in other
conditions such as APL-associated DIC, fibrinolysis
predominates over activation of coagulation leading
to a marked risk of bleeding in these patients.118
Management of DIC
The treatment of DIC is even more controversial
than the other aspects of this pathology. Very differ-
ent attitudes to this condition have been adopted in
clinical practice, mainly as a consequence of the lack
of studies conclusively showing the most efficient
treatment. Although large series from which to draw
definitive conclusions are not available, there is some
evidence to support a few currently held opinions. 
In the past DIC was associated with high mortali-
ty rates: the fact that the diseases underlying the DIC
are themselves often fatal must, however, be kept in
mind. This means that the cause of death in many
patients is due more to the progression of the under-
lying disease than to the progression of the DIC.119
Nevertheless, more reasonable and effective thera-
peutic strategies have favored longer patient survival.
The treatment of DIC must be logical and sequential,
and should include four different strategies: treat-
ment of the underlying disease or etiology treatment,
supportive therapy, replacement therapy and arrest
of the coagulation mechanism by heparin or other
thrombin inhibitors. 
Treatment of the underlying cause
The most important approach to DIC is the sup-
pression or attenuation of the trigger mechanism
through fast and vigorous treatment of the underly-
ing disease.3,4,6,120-122 This crucial point is more impor-
tant than the remaining therapeutic alternatives to
be described. We may not be able to arrest the mech-
anism which leads to the activation of the coagula-
tive pathways in some cases (e.g. neoplasia), but in
other instances appropriate treatment reduces the
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Table 3. Differential laboratory diagnosis of DIC, primary
hyperfibrinolysis and TTP.
DIC Primary hyperfibrinolysis TTP
Platelet count Low Normal Low
Fibrinogen Low Low Normal
FDP Elevated Elevated Normal
D-dimer Elevated Elevated Normal
ATIII Decreased Normal Normal
Schistocytosis Present Absent Present
Clotting times Prolonged Prolonged Normal
Lysis times Short Short Normal
stimulus which induces coagulation activation. It
seems clear that there are no useful therapies while
the underlying cause persists as illustrated by DIC
complicating obstetric disorders or sepsis. In the for-
mer cases, with the exception of amniotic fluid
embolism, evacuation of the uterus or, much less fre-
quently, hysterectomy, stop the DIC process; many
times a serious problem arises to convince the gyne-
cologist to operate on a patient who is bleeding. As
far as sepsis is concerned, adequate antibiotic often
succeeds in stopping DIC. 
Other therapeutic approaches to treating the DIC
directly are needed when the patient keeps on bleed-
ing after a reasonable period of time, although it is
not easy to establish what this period is since it
depends heavily on the location and severity of the
hemorrhagic episodes.
Supportive therapy
Supportive therapy must be started at the same
time as treatment of the underlying disease. Hyper-
volemia and hypoxia should be compensated, aci-
dosis should be controlled and a good electrolytic
balance should be achieved. The supportive treat-
ment must be adjusted to each specific clinical situ-
ation and each individual patient. In patients with
DIC and shock the measures to restore hydroelec-
trolytic balance, increase the volume of the vascular
compartment, and improve the cardiac deficit and
hypotension can sometimes in themselves be enough
to stop DIC but more often they help to establish the
conditions needed to make the subsequent treatment
efficient.
Replacement therapy
The aim of the blood replacement in DIC is to cor-
rect the consumption of platelets, coagulation fac-
tors and inhibitors in order to prevent or arrest the
hemorrhagic episodes. However, it has been hypoth-
esized that this treatment might feed the fire and cause
thrombosis in patients with active DIC, although this
issue has not been demonstrated in clinical practice123
or shown to be only marginal.124 Therefore, the use-
fulness of replacement therapy in some situations is,
at present, beyond all doubt. Whether replacement
therapy should start before or after the anticoagulant
treatment has been initiated remains controversial,
except for the cases in which the stimulus has been
totally eliminated. In our opinion, replacement ther-
apy is probably not necessary when the patient is not
bleeding and does not require surgery or other inva-
sive methods. In contrast, if the patient is bleeding or
requires an invasive procedure, replacement therapy
with cryoprecipitate, fresh-frozen plasma (FFP) and
platelet concentrates will probably be needed.
Replacement therapy is particularly important in
patients with DIC and underlying hepatic disease,
because in these conditions faster and more pro-
nounced reduction of factors can take place due to
the combination of increased consumption and
decreased synthesis caused by the liver disease. A
problem frequently arises when correcting thrombo-
cytopenia and a defect of coagulation factors in the
presence of severe hemorrhages and active DIC. In
such cases, although this sounds paradoxical, appli-
cation of the replacement therapy while under con-
tinuous heparin infusion cover can be useful.
When replacement therapy is going to be used, it
is important to elucidate which factors are deficient
and which could contribute to the persistence of
hemorrhage. Only the necessary products should be
administered; in other words, replacement therapy
must be as specific as possible.
When the use of replacement therapy has been
decided, the best choice is to infuse FFP, provided
that all coagulation factors and inhibitors are pre-
sent,125 at a dose of 10-15 mL/kg weight. When FFP
alone does not give a fibrinogen level above 0.5 g/L,
cryoprecipitate can then be infused at a ratio of 10 U
for every 2 or 3 U of plasma. Transfusing platelet con-
centrates at 1-2 U/kg weight is appropriate when the
platelet count is less than 20,000/µL or if there is
major bleeding and the platelet count is less than
50,000/µL .
Neither factor VIII nor factor IX concentrates
should be infused in these patients provided that fac-
tor VIII levels are not reduced in DIC.9,77 Factor IX
concentrate is potentially thrombogenic and may
itself cause DIC because it contains activated clot-
ting factors.126 Infusing hemoderivatives such as cryo-
precipitates, which are fibronectin-rich,127 has been
suggested to be useful because a decrease in fibro-
nectin levels has been shown in patients with DIC128
which could subsequently reduce the clearance of
activated coagulation factors.129
Heparin and other thrombin inhibitor therapy
The role of heparin in the treatment of DIC is very
controversial: while some physicians consider that
heparin can contribute to an increase in severe hem-
orrhagic complications, others claim this drug is use-
ful because of its ability to prevent the formation of
thrombi and subsequent organ dysfunction caused
by the ischemia. Heparin could also attenuate hem-
orrhagic complications by diminishing consumption
of factors and the secondary fibrinolysis. 
There are no objective data demonstrating that
heparin reduces morbidity and mortality in acute
DIC. Controlled prospective studies have not been
performed and one should be cautious when draw-
ing conclusions from retrospective analyses. In fact,
contradictory results have been obtained from such
analyses: while some reports in the literature support
the claim that heparin reduces the incidence of hem-
orrhage and increases survival in patients with DIC,8
others show that the use of heparin has no beneficial
effects.119,120
It is now, however, beyond all doubt that heparin
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can be useful in the treatment of the acute DIC caused
by some specific diseases. The most typical example
is purpura fulminans, in which heparin prevents tissue
damage due to thrombosis.46-49 The usefulness of
heparin is also well established in patients with DIC
caused by cancer, especially in chronic DIC associat-
ed with recurrent thrombosis45,130 but also when it is
associated with hyperfibrinolysis and hemorrhage.131
Chronic DIC secondary to other causes such as large
aneurysms,132 Kasabach-Merrit syndrome133 and a
retained dead fetus134,135 may also improve with
heparin. A few studies have shown that heparin is use-
ful in controlling the DIC associated with APL,136-139
although two other large retrospective studies were
not able to demonstrate that treatment with heparin
improves results in this condition.127,140 Heparin does
not seem to exert beneficial effects in other situations
such as sepsis, obstetric complications (except in
retained dead fetus syndrome) or liver disease. 
Even when there is agreement over the usefulness of
heparin, there is still controversy about the best dose
to give and the way to give it. It seems that low dos-
es, in the range of 5-10 U/kg/h given by continuous
intravenous infusion, should be enough to reverse the
coagulopathy in patients with acute DIC.72,121,141,142
Some authors claim that the subcutaneous route is
as efficient as intravenous infusion.3,6 Finally, the use
of low molecular weight heparins has been shown to
be useful in experimental models of endotoxin-
induced DIC in rabbits,143 although it has only been
evaluated in one clinical study which showed that
50% of the treated patients improved.144
Since heparin requires ATIII to exert its anticoagu-
lant activity and ATIII levels can be low in DIC, heparin
therapy could sometimes be inefficient in these
patients. The use of direct thrombin inhibitors could
give better results because their activity is unrelated to
ATIII levels. The direct thrombin inhibitor hirudin has
been experimentally tested with good results in a few
animal models,145-148 although its clinical benefit has
only been evaluated in two small studies which cannot
be considered conclusive.149,150
The infusion of ATIII concentrates, with or without
heparin, has been shown to be useful in experimental
models of DIC in rabbits27 and dogs.30 Moreover,
some clinical studies have described a reduction in
mortality together with disappearance of the DIC.
However, the number of patients included in these
studies is small which makes it difficult to draw defin-
itive conclusions, although the available data support
the efficacy of this treatment.151-158 A large, prospective
and randomized clinical trial should, therefore, be per-
formed to demonstrate clearly whether the use of AT-
III concentrates is appropriate as a treatment of
patients with DIC.
The infusion of activated protein C concentrates
has been shown to prevent DIC and mortality in an
animal model of sepsis;35 moreover, an anti-protein
C monoclonal antibody previously administered pro-
voked a more severe DIC pattern.159 It has been pro-
posed that the presence of activated protein C not
only serves as an anticoagulant but also protects
against the lethal effect of endotoxin shock.160 These
studies strongly suggest a beneficial role for protein
C replacement therapy in patients with DIC. There is
very little clinical experience with the use of protein C
concentrates in patients with DIC so far, but the pre-
liminary results appear promising.161-162
Other treatment modalities
Antifibrinolytic drugs such as EACA and tranexam-
ic acid can diminish bleeding caused by hyperfibrinol-
ysis. However, they may also unmask underlying coag-
ulation and convert a bleeding disorder into a throm-
botic condition, which have made many authors con-
sider their use contraindicated in DIC.163-164 Neverthe-
less, the beneficial effects of antifibrinolytic drugs can
be greater than the risks when DIC is associated with
hyperfibrinolysis and intense hemorrhagic episodes,
especially when there is not much thrombin forma-
tion, as frequently happens in patients with APL.
Some reports describe that these patients can be suc-
cessfully treated with EACA or tranexamic acid to
reduce hemorrhage with no increase in the risk of
thrombosis.165-167 Antifibrinolytic drugs have also
been successfully used in patients with DIC associat-
ed with Kasabach-Merrit syndrome168-170 and in
patients who have laboratory evidence of hyperfibri-
nolysis with depletion of physiologic plasmin
inhibitors but who bleed despite aggressive replace-
ment therapy.84 When used to treat DIC, antifibri-
nolytic drugs are usually given in conjunction with
heparin to minimize the risk of thrombosis. Doses of
10-15 mg/kg/h of EACA are appropriate.165 In the
case of patients with giant hemangiomas the treat-
ment with antifibrinolytic drugs is not associated with
heparin.
Products such as gabexate, aprotinin, DDAVP, t-PA
or a genetically engineered mutant, a1-antitrypsin
Pittsburgh, a mutant serpin that inhibits thrombin,
factor XIIa, factor XIa, and kallikrein have been used,
but in purely experimental animal models; their use-
fulness in DIC patients has only been tested in very
occasional anecdotally reported cases.171-175
It has recently been suggested that intervention at
the level of endotoxins or cytokines (e.g. by specific
monoclonal antibodies) may result in treatment or
prevention of DIC, specially in patients with sepsis.
There are some studies, both experimental and clin-
ical, in which anti-endotoxin polyclonal or mono-
clonal antibodies, anti-TNF-a antibodies, TNF-a
receptor:Fc recombinant fusion protein, recombi-
nant IL-1 receptor antagonist, anti-interleukin-6 anti-
bodies, pentoxifylline or ibuprofen have been used.
The results, although not totally conclusive, are quite
promising in some cases, which is leading many
researchers to focus on the potential beneficial role
of these agents.176-192 New more specific strategies
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aimed at the treatment or prevention of DIC may
include inhibition of the extrinsic pathway of blood
coagulation; to this end anti-tissue factor and anti-
factor VIIa antibodies have been used and the effect
of immunodepletion of TFPI or administration of
recombinant TFPI have been studied in a variety of
experimental models, with promising results which
suggest that these strategies could also be successful
when applied to human DIC.14,15,25,192-194
To conclude, until these new strategies clearly show
their efficacy, the treatment of acute generalized,
widespread bleeding in general and the specific treat-
ment of DIC must be decided according to a scheme
similar to that given in Figure 2. 
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